Minimising Risk in Clinical Trials
Global regulators have been steadily increasing the level of scrutiny of regulations and calling for a more effective risk-based approach.
In Marsh’s Report, Minimising Risks in Clinical Trials, we follow up on a recent ‘thought leadership’ event hosted by Marsh in partnership with One Nucleus. The Report highlights some of the trends in the monitoring and enforcement of Good Clinical Practice and provides a framework for managing risk in the planning and conduct of a clinical trial.
Risk identification and mitigation are the primary defence against trial interruption. There are multiple sources of professional advice and guidance to support this. However, these are not the only safeguard.
To find out more, download the report.